PFIZER INC Annual Report, Year Ended Dec 31, 2008

Pfizer Inc.'s 2008 Form 10-K filing highlights a year of significant strategic moves and robust performance despite challenges from patent expirations. The company maintained its position as a global pharmaceutical leader, with its Pharmaceutical segment contributing over 91% of total revenues, driven by strong performances from key products like Lipitor and Lyrica. However, the loss of U.S. exclusivity for Norvasc and patent expirations for other major drugs presented headwinds. Pfizer also made substantial investments in research and development, totaling $7.9 billion, to fuel its future pipeline. A major announcement in early 2009, the definitive merger agreement to acquire Wyeth for $68 billion, signals a significant future growth strategy aimed at expanding its product portfolio and global reach. Operationally, Pfizer demonstrated resilience with international revenues accounting for a substantial 57.7% of total revenue, benefiting from favorable foreign exchange rates. The company navigated a complex regulatory environment and increasing pricing pressures from managed care organizations and government programs. Key product successes in both the Pharmaceutical and Animal Health segments underscore Pfizer's diversified strengths, while strategic acquisitions throughout 2008 aimed to bolster its presence in areas like immunotherapy and central nervous system disorders.